visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery |
Data: | 2022 |
Resum: | Self-assembling non-immunoglobulin scaffold proteins are a promising class of nanoscale carriers for drug delivery and interesting alternatives to antibody-based carriers that are not sufficiently efficient in systemic administration. To exploit their potentialities in clinics, protein scaffolds need to be further tailored to confer appropriate targeting and to overcome their potential immunogenicity, short half-life in plasma and proteolytic degradation. We have here engineered three human scaffold proteins as drug carrier nanoparticles to target the cytokine receptor CXCR4, a tumoral cell surface marker of high clinical relevance. The capability of these scaffolds for the selective delivery of Monomethyl auristatin E has been comparatively evaluated in a disseminated mouse model of human, CXCR4+ acute myeloid leukemia. Monomethyl auristatin E is an ultra-potent anti-mitotic drug used against a range of hematological neoplasias, which because of its high toxicity is not currently administered as a free drug but as payload in antibody-drug conjugates. The protein nanoconjugates generated here offer a collective strength of simple manufacturing process, high proteolytic and structural stability and multivalent ligand receptor interactions that result in a highly efficient and selective delivery of the payload drug and in a potent anticancer effect. The approach shown here stresses this class of human scaffold proteins as promising alternatives to antibodies for targeted drug delivery in the rapidly evolving drug development landscape. |
Ajuts: | Agencia Estatal de Investigación PID2019-105416RB-I00 Ministerio de Ciencia e Innovación BIO2016-76063-R Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-229 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1395 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-865 Instituto de Salud Carlos III PI18/00650 Instituto de Salud Carlos III PI20/00400 Ministerio de Ciencia e Innovación RTC-2017-6125-1 Ministerio de Ciencia e Innovación FPU18/04615 Instituto de Salud Carlos III CP19/00028 |
Nota: | Altres ajuts: Marató de TV3 Foundation (grant 201941-30-31-32) |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió acceptada per publicar |
Matèria: | Scaffold proteins ; Self-assembling ; Nanoparticles ; Drug delivery ; Biomaterials |
Publicat a: | Journal of Controlled Release, Vol. 343 (March 2022) , p. 277-287, ISSN 1873-4995 |
Postprint 35 p, 1.3 MB |